ストックスクリーナーアプリを入手
1.80
7.26%
-0.01
Beyondspring Inc (BYSI) 最新ニュース
Form 4 BeyondSpring Inc For: 6 July By Investing.com - Investing.com Canada
BeyondSpring (BYSI) CEO Qiu Min reports direct holding of 2,498 Ordinary Shares - Stock Titan
BeyondSpring (BYSI) CEO awarded 100,000 stock options at $1.75 strike price - Stock Titan
BeyondSpring (BYSI) CFO Li Na submits initial Form 3 ownership filing - Stock Titan
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Per‑Share Loss Amid Ongoing Pipeline FocusBalance Sheet Strength - dars.gov.et
BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant - Stock Titan
BeyondSpring Inc.(NasdaqCM: BYSI) dropped from Russell 3000E Growth Benchmark - marketscreener.com
BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
BYSI Q1 2026 Earnings: Narrowing Losses Amid Pipeline Progress, Stock Gains 5.6%Pre-Earnings Drift - dars.gov.et
Beyondspring Inc (BYSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Price to sales forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Enterprise value to revenue forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Beyondspring Inc (BYSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BeyondSpring Inc. Actuals & Estimates (NASDAQ:BYSI) - TradingView
Beyondspring Inc (BYSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beyondspring Inc (BYSI) Institutional Confidence - TradingKey
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Losses Amid Strategic Clinical ProgressAnalyst Drop Coverage - dars.gov.et
Beyondspring Inc (BYSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beyondspring Inc (BYSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beyondspring Inc (BYSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beyondspring Inc (BYSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beyondspring Inc (BYSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BYSI Q1 2026 Earnings: Net Loss Narrows Amid Ongoing Clinical DevelopmentProfitability Analysis - newsline.com
BYSI Q1 2026 Earnings: Pipeline Progress Amidst Pre-Revenue PhaseNet Profit Margin - newsline.com
BeyondSpring Announces Major Leadership Transition and New CEO - The Globe and Mail
BYSI Q1 2026 Earnings: Loss per Share of $0.05, Stock Declines Amid Quiet QuarterEarnings Miss Streak - newsline.com
BeyondSpring names new CEO as founder transitions to chairman role - StreetInsider
BeyondSpring Elevates Min Qiu to CEO, Names Na Li CFO in Leadership Transition - citybiz
BeyondSpring names new CEO, CFO as founder shifts to chairman role By Investing.com - Investing.com South Africa
BeyondSpring Inc. Announces Appointment of Na Li as Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
BeyondSpring names new CEO, CFO as founder shifts to chairman role - Investing.com Nigeria
BeyondSpring (NASDAQ: BYSI) overhauls leadership to drive DUBLIN-4 lung cancer program - Stock Titan
BeyondSpring Inc. Announces Leadership Transition to Enhance Focus on DUBLIN-4 Program and Plinabulin Development - Quiver Quantitative
BeyondSpring: Lan Huang Remains Chairman >BYSI - Moomoo
BeyondSpring Announces Leadership Transition to Deliver - GlobeNewswire
BeyondSpring (BYSI) Shares Promising Phase 2 Findings for Lung C - GuruFocus
BeyondSpring reports phase 2 lung cancer trial results at ASCO - Investing.com
BeyondSpring reports phase 2 lung cancer trial results at ASCO By Investing.com - Investing.com Canada
Lung cancer trial tests drug trio after immunotherapy, 58% alive at 2 years - Stock Titan
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 - GlobeNewswire
BeyondSpring (BYSI) Faces Selling Pressure: Support Levels Tested After 2.33% DeclineSynthetic Short - The Legal Advocate
BYSI Stock Chart | BEYONDSPRING INC (NASDAQ:BYSI) - ChartMill
BYSIBeyondSpring Inc Stock Price and Quote - Finviz
BeyondSpring Q1 2026 Earnings: Narrowed Loss Per Share and Positive Stock MovementEarnings Decline Risk - The Legal Advocate
BeyondSpring (BYSI) Q1 2026 Earnings: Narrowing Loss and No Revenue as Clinical-Stage Biotech Advances PipelineProfit Recovery Report - The Legal Advocate
BYSI Q1 2026 Earnings: Narrow Loss and Modest Stock Gain as Pipeline Progress ContinuesInterim Report - The Legal Advocate
BeyondSpring Q1 2026 Earnings: Narrowing Loss Highlights Pipeline Progress Amid Zero RevenueTrending Buy Opportunities - Newser
BeyondSpring Inc. to Present Study 303 on Plinabulin Combination Therapy for NSCLC at ASCO 2026 - Quiver Quantitative
Phase 2 plinabulin combo in resistant NSCLC to appear at 2026 ASCO - Stock Titan
BYSI BeyondSpring beats Q4 EPS estimates by 11 but shares drop 25 on zero revenueValue Pick - Newser
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting - GlobeNewswire
Number of shareholders of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Lan Huang trust gifts 260,582 BeyondSpring (BYSI) shares in Form 4 filing - Stock Titan
BeyondSpring (BYSI) insiders report 14.1% each; trust transfers disclosed - Stock Titan
BeyondSpring Reports Q1 2026 Financial Results: Plinabulin Pipeline Progress and SEED Therapeutics Clinical Update – Minichart - Minichart
BeyondSpring Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
1.83%
3.59%
大文字化:
|
ボリューム (24 時間):